유럽 연합 - 영어 - EMA (European Medicines Agency)

actavis group ptc ehf - rivastigmine hydrogen tartrate - dementia; alzheimer disease; parkinson disease - psychoanaleptics, - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia in patients with idiopathic parkinson's disease.

이집트 - 영어 - EDA (Egyptian Drug Authority)

el nile. - tablet - 5 mg

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg); levodopa, quantity: 200 mg - tablet, uncoated - excipient ingredients: iron oxide red; crospovidone; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; calcium hydrogen phosphate; mannitol; pregelatinised maize starch; docusate sodium; ethylcellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg); levodopa, quantity: 100 mg - capsule, hard - excipient ingredients: mannitol; indigo carmine; iron oxide yellow; hypromellose; titanium dioxide; magnesium stearate; purified talc; gelatin; hydrogenated vegetable oil; povidone; calcium hydrogen phosphate dihydrate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; iron oxide red; ethanol absolute; potassium hydroxide; ammonia - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism. madopar hbs is indicated for patients presenting with all types of fluctuations in response (i.e. "peak dose dyskinesia" and "end of dose deterioration") and for better control of nocturnal symptoms.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 200 mg; benserazide hydrochloride, quantity: 57 mg (equivalent: benserazide, qty 50 mg) - capsule, hard - excipient ingredients: iron oxide yellow; magnesium stearate; indigo carmine; povidone; gelatin; titanium dioxide; purified talc; microcrystalline cellulose; iron oxide red - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg); levodopa, quantity: 50 mg - tablet, dispersible - excipient ingredients: magnesium stearate; pregelatinised maize starch; citric acid; microcrystalline cellulose - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, dispersible - excipient ingredients: citric acid; microcrystalline cellulose; magnesium stearate; pregelatinised maize starch - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; docusate sodium; iron oxide red; calcium hydrogen phosphate; magnesium stearate; ethylcellulose; mannitol - parkinson's disease and parkinsonian symptoms including post- encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - capsule, hard - excipient ingredients: indigo carmine; purified talc; gelatin; iron oxide red; magnesium stearate; povidone; microcrystalline cellulose; titanium dioxide - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.

오스트레일리아 - 영어 - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - levodopa, quantity: 50 mg; benserazide hydrochloride, quantity: 14.25 mg (equivalent: benserazide, qty 12.5 mg) - capsule, hard - excipient ingredients: indigo carmine; iron oxide black; magnesium stearate; microcrystalline cellulose; purified talc; titanium dioxide; povidone; mannitol; gelatin - parkinson's disease and parkinsonian symptoms including post-encephalitic and toxic forms, but excluding drug induced parkinsonism.